Relationship between Change in Bone Mineral Density of Lumbar Spine and Risk of New Vertebral and Nonvertebral Fractures: A Meta‐Analysis

Orthopaedic Surgery

Mohamed E A Abdelrahim¹  Tong‐ya Guo²  Feng Yuan³  Xiao‐ping Liu⁴  Liang Chen⁵  Bo Zhou⁵  Zhen‐huan Jiang⁵ 

[1] Clinical Pharmacy Department Faculty of Pharmacy, Beni‐Suef University Beni‐Suef Egypt;Department of Bone and Joint Surgery Xuzhou Central Hospital Xuzhou China;Department of Orthopaedic Surgery Shanghai Jiao Tong University Affiliated Sixth People's Hospital Shanghai 200233 China;Department of Orthopaedics Suzhou Kowloon Hospital Shanghai Jiao Tong University School of Medicine Suzhou China;Department of Orthopaedics Yixing People's Hospital Yixing China;

关键词: Bone mineral density;    Lumbar spine;    Nonvertebral fracture;    Postmenopausal females;    Vertebral fracture;   

DOI  :  10.1111/os.13184

来源: DOAJ

【 摘 要 】

Studies have shown that the change in lumbar spine bone mineral density with different osteoporosis drugs had a beneficial effect on the frequency of new vertebral and nonvertebral fractures in postmenopausal females, but their results were conflicting. This meta‐analysis was performed to evaluate this relationship. A systematic literature search up to May 2020 was performed and 20 studies with 73,390 postmenopausal females were included; of them, a total of 41,980 were treated with osteoporosis drugs and 31,410 with placebo. They reported relationships between the change in lumbar spine bone mineral density and the frequency of new vertebral and nonvertebral fractures in postmenopausal females. Odds ratio (OR) with 95% confidence intervals (CIs) was calculated comparing the osteoporosis drugs to placebo effect on the frequency of new vertebral and nonvertebral fractures in postmenopausal females using the dichotomous method with a random or fixed‐effect model. Treatment with osteoporosis drugs had significantly lower frequency of new vertebral fractures (OR, 0.53; 95% CI, 0.45–0.63, P < 0.001) and nonvertebral fractures (OR, 0.82; 95% CI, 0.78–0.87, P < 0.001) compared to placebo in postmenopausal females. Treatment with osteoporosis drugs had a significantly lower frequency of new vertebral and nonvertebral fractures compared to placebo in postmenopausal females. This relationship forces us to recommend osteoporosis drugs in postmenopausal females to avoid any possible new fractures. A cost‐effective study is recommended.

【 授权许可】

Unknown